Skip to main content

2 Result(s)

within Murali Kesavan Remove this filter

and

  1. Article

    Open Access

    A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

    This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients w...

    Stephen W. Booth, Toby A. Eyre, John Whittaker, Leticia Campo, Lai Mun Wang… in BMC Cancer (2021)

    Download PDF (1159 KB) View Article

  2. Article

    Open Access

    Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

    Rituximab-based chemoimmunotherapy has resulted in a marked improvement in the survival of diffuse large B cell lymphoma (DLBCL). We reflect upon the history front-line (1L) therapy and highlight advances in m...

    Murali Kesavan, Toby A. Eyre, Graham P. Collins in Current Hematologic Malignancy Reports (2019)

    Download PDF (611 KB) View Article